NASDAQ$CABA
Cabaletta Bio Inc · Q1 2020 earnings
Q1 2020 earnings · · Investor relations
Briefing
Cabaletta Bio announced financial results for the first quarter ended March 31, 2020.
Cabaletta Bio reported first quarter 2020 financial results, with research and development expenses at $4.6 million and general and administrative expenses at $3.3 million. Cash and cash equivalents totaled $131.0 million as of March 31, 2020.
- FDA granted Fast Track Designation to DSG3-CAART for mucosal pemphigus vulgaris (mPV).
- Phase 1 DesCAARTesTM trial is ready to launch pending lifting of COVID-19 related clinical trial activity restrictions.
- IND-enabling studies for MuSK-CAART are planned to be initiated in 2020.
- Cash and cash equivalents are expected to fund operating plan through at least the third quarter of 2022.
Headline financials
Revenue & EPS history
Cabaletta Bio · Revenue · Quarterly
$0
Forward guidance
Cabaletta Bio expects that its current cash and cash equivalents will enable it to fund its operating plan through at least the third quarter of 2022.
Historical earnings impact
How earnings announcements have historically affected this stock's price.
Avg. return before/after earnings
Based on 19 quarterly earnings reports · overlaid with Q1 2020
+2.7%
Avg return
Earnings day
+3.2%
Avg return
5 days after
+5.3%
Avg return
30 days after
67%
16 / 24 earnings
Positive
+22.7%
Q3 2022
Best reaction
-24.4%
Q3 2024
Worst reaction
| Quarter | Report date | Reaction (Day 0) | +5 days | +30 days |
|---|---|---|---|---|
| Q4 2026 | -7.8% | -9.0% | -16.2% | |
| Q3 2025 | -5.0% | -9.4% | -5.1% | |
| Q1 2025 | -0.6% | +6.9% | -2.9% | |
| Q4 2024 | +12.8% | -28.4% | -14.8% | |
| Q3 2024 | -24.4% | -36.7% | -29.7% | |
| Q1 2024 | +12.4% | +14.7% | -5.1% | |
| Q4 2023 | -4.2% | -6.4% | -26.4% | |
| Q3 2023 | +4.0% | +1.6% | -5.6% | |
| Q2 2023 | +10.0% | +10.4% | +12.0% | |
| Q1 2023 | +1.6% | +7.0% | -1.2% | |
| Q4 2022 | +9.3% | +4.3% | +5.4% | |
| Q3 2022 | +22.7% | +84.0% | +207.2% | |
| Q2 2022 | +19.5% | +17.2% | -26.3% | |
| Q1 2022 | +21.1% | +52.8% | -3.3% | |
| Q4 2021 | +14.6% | +32.7% | +6.4% | |
| Q3 2021 | +2.4% | -5.3% | -19.1% | |
| Q2 2021 | +2.0% | +1.9% | +58.0% | |
| Q1 2021 | -6.6% | -14.0% | -7.2% | |
| Q4 2020 | +1.7% | -4.0% | -8.7% | |
| Q3 2020 | +6.7% | +7.1% | +19.3% | |
| Q2 2020 | +6.4% | +4.6% | -15.8% | |
| Q1 2020 | -9.3% | -8.0% | -8.0% | |
| Q4 2019 | +0.3% | -7.6% | +10.7% | |
| Q3 2019 | -23.7% | -38.7% | +3.7% | |
| Q2 2019 | — | — | — | |
| Q1 2019 | — | — | — | |
| Q4 2018 | — | — | — | |
| Q3 2018 | — | — | — | |
| Q2 2018 | — | — | — | |
| Q1 2018 | — | — | — |
Discussion
Share your read of this quarter. Sign-in carries your eToro identity.
Join the conversation
Sign in with eToro to post your read of this quarter and vote on others'.
Sign in with eToro